These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? Di Federico A; De Giglio A; Parisi C; Gelsomino F Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370 [TBL] [Abstract][Full Text] [Related]
5. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8 Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171 [TBL] [Abstract][Full Text] [Related]
6. AXL targeting restores PD-1 blockade sensitivity of Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873 [TBL] [Abstract][Full Text] [Related]
7. Emerging Therapeutic Implications of STK11 Mutation: Case Series. Laderian B; Mundi P; Fojo T; E Bates S Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674 [TBL] [Abstract][Full Text] [Related]
8. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602 [TBL] [Abstract][Full Text] [Related]
9. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Mitchell KG; Parra ER; Zhang J; Nelson DB; Corsini EM; Villalobos P; Moran CA; Skoulidis F; Wistuba II; Fujimoto J; Roth JA; Antonoff MB; Ann Thorac Surg; 2020 Oct; 110(4):1131-1138. PubMed ID: 32442617 [TBL] [Abstract][Full Text] [Related]
10. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906 [TBL] [Abstract][Full Text] [Related]
12. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186 [TBL] [Abstract][Full Text] [Related]
13. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612 [TBL] [Abstract][Full Text] [Related]
14. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843 [TBL] [Abstract][Full Text] [Related]
15. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570 [TBL] [Abstract][Full Text] [Related]
16. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008 [TBL] [Abstract][Full Text] [Related]
17. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Gao Y; Ge G; Ji H Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642 [TBL] [Abstract][Full Text] [Related]
18. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells. Nishimura S; Yashiro M; Sera T; Yamamoto Y; Kushitani Y; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Okuno T; Murakami Y; Ohira M Carcinogenesis; 2020 Nov; 41(11):1616-1623. PubMed ID: 32236518 [TBL] [Abstract][Full Text] [Related]
19. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC. Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328 [TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. He N; Kim N; Song M; Park C; Kim S; Park EY; Yim HY; Kim K; Park JH; Kim KI; Zhang F; Mills GB; Yoon S Mol Cancer Ther; 2014 Oct; 13(10):2463-73. PubMed ID: 25122068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]